Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Can we safely target the WNT pathway?
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Paroxysmal Hypothermia in Two Patients with Multiple Sclerosis.
Remote effects of intermittent theta burst stimulation of the human pharyngeal motor system.
Sativex(®) in multiple sclerosis spasticity: a cost-effectiveness model.
Immune modulating peptides for the treatment and suppression of multiple sclerosis.
[Differential diagnosis of late-stage neuroborreliosis with affection of the central nervous system.]
Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura and hemolytic uremic syndrome reports with SC interferon beta-1a.
Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
Uncovering Cryptic Glycan Markers in Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE).
Tapered withdrawal of phenytoin removes protective effect in EAE without inflammatory rebound and mortality.
The role of complementary and alternative medicine in therapy of multiple sclerosis.
Efficient transdifferentiation of human adipose-derived stem cells into Schwann-like cells: A promise for treatment of demyelinating diseases.
Newly diagnosed multiple sclerosis in state of Qatar.
Modeling the heterogeneity of multiple sclerosis in animals.
[Chronic cerebrospinal venous insufficiency--pathophysiology and treament].
Multiple sclerosis.
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
FDA approves injectable drug to treat opioid-dependent patients
Complex molecular and functional outcomes of single versus sequential cytokine stimulation of rat microglia.
About Tysabri
Demyelinating Diseases: Myeloperoxidase as an Imaging Biomarker and Therapeutic Target.
Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation.
No MRI evidence of cortical lesions in neuromyelitis optica.
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification.

Pages